In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $1.47.
LeBoyer covers the Healthcare sector, focusing on stocks such as GeoVax Labs, Ocugen, and PDS Biotechnology. According to TipRanks, LeBoyer has an average return of -10.4% and a 25.50% success rate on recommended stocks.
Currently, the analyst consensus on MAIA Biotechnology, Inc. is a Moderate Buy with an average price target of $14.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.42 and a one-year low of $0.82. Currently, MAIA Biotechnology, Inc. has an average volume of 342.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MAIA Biotechnology, Inc. (MAIA) Company Description:
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company’s lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Read More on MAIA:
- MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
- MAIA Biotechnology Advances with Phase 2 Lung Cancer Trial
- MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
- MAIA Biotechnology completes enrollment in THIO-101 Phase 2 trial
- MAIA Biotechnology Announces Flexible Stock Offering Program
